Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study Our phase II trial randomly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback